As of Apr 29
| -0.2299 / -1.76%|
The 5 analysts offering 12-month price forecasts for Redhill Biopharma Ltd have a median target of 26.00, with a high estimate of 33.00 and a low estimate of 23.00. The median estimate represents a +102.81% increase from the last price of 12.82.
The current consensus among 5 polled investment analysts is to Buy stock in Redhill Biopharma Ltd. This rating has held steady since April, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.